BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11861385)

  • 1. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.
    Carlomagno F; Vitagliano D; Guida T; Napolitano M; Vecchio G; Fusco A; Gazit A; Levitzki A; Santoro M
    Cancer Res; 2002 Feb; 62(4):1077-82. PubMed ID: 11861385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
    Carlomagno F; Vitagliano D; Guida T; Ciardiello F; Tortora G; Vecchio G; Ryan AJ; Fontanini G; Fusco A; Santoro M
    Cancer Res; 2002 Dec; 62(24):7284-90. PubMed ID: 12499271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
    Carlomagno F; Vitagliano D; Guida T; Basolo F; Castellone MD; Melillo RM; Fusco A; Santoro M
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1897-902. PubMed ID: 12679489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting.
    Carniti C; Perego C; Mondellini P; Pierotti MA; Bongarzone I
    Cancer Res; 2003 May; 63(9):2234-43. PubMed ID: 12727845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.
    Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.
    Vitagliano D; Carlomagno F; Motti ML; Viglietto G; Nikiforov YE; Nikiforova MN; Hershman JM; Ryan AJ; Fusco A; Melillo RM; Santoro M
    Cancer Res; 2004 Jun; 64(11):3823-9. PubMed ID: 15172989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
    Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
    Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
    Carlomagno F; Guida T; Anaganti S; Vecchio G; Fusco A; Ryan AJ; Billaud M; Santoro M
    Oncogene; 2004 Aug; 23(36):6056-63. PubMed ID: 15184865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
    Powell DJ; Russell J; Nibu K; Li G; Rhee E; Liao M; Goldstein M; Keane WM; Santoro M; Fusco A; Rothstein JL
    Cancer Res; 1998 Dec; 58(23):5523-8. PubMed ID: 9850089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.
    Barone MV; Sepe L; Melillo RM; Mineo A; Santelli G; Monaco C; Castellone MD; Tramontano D; Fusco A; Santoro M
    Oncogene; 2001 Oct; 20(48):6973-82. PubMed ID: 11704822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
    Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
    Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas.
    Bongarzone I; Butti MG; Coronelli S; Borrello MG; Santoro M; Mondellini P; Pilotti S; Fusco A; Della Porta G; Pierotti MA
    Cancer Res; 1994 Jun; 54(11):2979-85. PubMed ID: 8187085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas.
    Jhiang SM; Sagartz JE; Tong Q; Parker-Thornburg J; Capen CC; Cho JY; Xing S; Ledent C
    Endocrinology; 1996 Jan; 137(1):375-8. PubMed ID: 8536638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice.
    Powell DJ; Russell JP; Li G; Kuo BA; Fidanza V; Huebner K; Rothstein JL
    Oncogene; 2001 May; 20(25):3235-46. PubMed ID: 11423973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
    Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
    Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.
    Borrello MG; Pelicci G; Arighi E; De Filippis L; Greco A; Bongarzone I; Rizzetti M; Pelicci PG; Pierotti MA
    Oncogene; 1994 Jun; 9(6):1661-8. PubMed ID: 8183561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ret-mediated mitogenesis requires Src kinase activity.
    Melillo RM; Barone MV; Lupoli G; Cirafici AM; Carlomagno F; Visconti R; Matoskova B; Di Fiore PP; Vecchio G; Fusco A; Santoro M
    Cancer Res; 1999 Mar; 59(5):1120-6. PubMed ID: 10070972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rearrangement of the RET gene in papillary thyroid carcinoma].
    Wiench M; Włoch J; Oczko M; Gubała E; Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():64-71. PubMed ID: 12182064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.